Get started
Author

Dominique Mille

Observed names: Dominique MILLE, Mille, Dominique
OpenAlex ID: A5111832733
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · The Lancet Oncology · 381
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
2020 · Astrid Lièvre, Anthony Turpin, et al. · European Journal of Cancer · 163
PDF
Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
2003 · Patrick Mismetti, Dominique Mille, et al. · PubMed · 93
Economic Impact of Harmonizing Medical Practices: Compliance With Clinical Practice Guidelines in the Follow-Up of Breast Cancer in a French Comprehensive Cancer Center
2000 · Dominique Mille, Thomas Roy, et al. · Journal of Clinical Oncology · 65
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 31
In-vitro circadian rhythm of murine bone marrow progenitor production
2002 · Philippe Bourin, Arnaud F. Ledain, et al. · Chronobiology International · 29
Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients
2011 · Jean-Philippe Jacquin, Cyrus Chargari, et al. · American Journal of Clinical Oncology · 14
Formalismes pour une mémoire de formation à base d'annotations : articuler sémantique implicite et explicite.
2003 · Azouaou, Faiçal, Desmoulins, Cyrille, et al. · HAL · 9
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024 · Florence Joly, Fernando Bazan, et al. · JNCI Cancer Spectrum · 5
PDF
Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
2022 · Suzette Delaloge, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 2
Description des modalités pratiques de prescription d’un facteur de croissance de la lignée granulocytaire (G-CSF) chez les patientes recevant une chimiothérapie pour un cancer du sein : étude Opaline
2015 · William Jacot, Eric-Charles Antoine, et al. · Bulletin du Cancer · 2
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
2024 · David Tougeron, Frederic Bibeau, et al. · European Journal of Cancer · 1
Raltitrexed in the management of metastatic colorectal cancer: The COMET study.
2015 · Jérôme Desramé, Louis-Marie Dourthe, et al. · Journal of Clinical Oncology · 1
Works count: 13
Citation count: 796
H-index: 8
I10-index: 7
Year
Topic
Type